ASPIRIN PROPHYLAXIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

阿司匹林预防阵发性睡眠性血红蛋白尿

• 批准号: 2571440
• 负责人: S ROSENFELD
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2571440
• 关键词: aspirin; cardiovascular disorder chemotherapy; chemoprevention; clinical research; human subject; interview; paroxysmal nocturnal hemoglobinuria; platelet activation; venous thrombosis

Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic hemolytic disorder characterized by the loss of membrane proteins that protect erythrocytes from complement mediated lysis. It is associated with a high risk of major thrombotic events, most commonly thrombosis of large intraabdominal veins. Most patients who die of their disease die of thrombosis. While the cause of this predisposition is unknown, we have recently demonstrated abnormal levels of platelet activation in patients with PNH. We have a protocol in place for treating patients with PNH with low dose oral aspirin. This protocol is designed to detect in vitro changes in platelet activation before and after aspirin administration. PNH is a rare disorder, and the protocol involves several visits to the National Institutes of Health campus over a month (platelet studies must be performed on fresh samples). Because of the difficulty of recruiting patients to this protocol, we are amending it to make it more convenient for patients.

阵发性睡眠性血红蛋白尿（PNH）是一种慢性溶血性疾病 以保护膜蛋白缺失为特征的疾病 来自补体介导的裂解的红细胞。它与 发生重大血栓事件的高风险，最常见的是 腹内静脉大。大多数患者死于疾病 死于血栓。虽然这种倾向的原因是 未知，我们最近发现血小板水平异常 PNH 患者的激活。 我们制定了治疗低血压 PNH 患者的方案 剂量口服阿司匹林。该协议旨在体外检测 阿司匹林前后血小板活化的变化 行政。 PNH 是一种罕见疾病，治疗方案涉及 多次访问美国国立卫生研究院校园 月（必须对新鲜样本进行血小板研究）。因为 考虑到招募患者参与该方案的难度，我们 对其进行修改，以方便患者使用。